Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.62 HKD | -0.71% | -.--% | -.--% |
Apr. 01 | Venus Medtech Trims Loss in 2023 as Revenue Grows Nearly 21% | MT |
Mar. 28 | Venus Medtech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company's enterprise value to sales, at 3.64 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-.--% | 314M | B | ||
+9.39% | 125B | A- | ||
-8.73% | 10.48B | A- | ||
-3.67% | 8.42B | C | ||
+10.98% | 6.82B | C | ||
+26.18% | 4.96B | B+ | ||
+7.13% | 3.41B | C- | ||
-1.22% | 3.04B | B- | ||
-10.69% | 2.1B | - | - | |
-11.48% | 1.97B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
- Stock Market
- Equities
- 2500 Stock
- Ratings Venus Medtech (Hangzhou) Inc.